High dose vitamin C enhances immune system profiles and immunotherapy treatment outcomes (PD-1 inhibitors) according to a lung cancer model (mouse). High-dose vitamin C significantly increased CD8+ T cell activity and when administered in combination, significant antitumor effects were observed, and tumor growth was considerably reduced compared with treatment with either anti-PD1 or high-dose vitamin C alone. The high-dose vitamin C increased the infiltration of CD8+ T cells independently of anti-PD1 but increased the killing activity of anti-PD1. This research tends to match our clinic experiences throughout the years alongside checkpoint inhibitors (i.e. Keytruda, Optivo, etc.). There appears to be clinical value in the combination and has also been further supportive from an in integrative model in humans from Austria that incorporated low dose immunotherapy, hyperthermia, and vitamin C.
